Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

156
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
156
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

18.0K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
18.0K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism01:21

Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism

682
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
682

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifteen years and counting: A journey of interventions to sustain an arteriovenous graft hemodialysis access.

The journal of vascular access·2025
Same author

Repetitive Negative Thinking and Sexual Functioning in Portuguese Men and Women: A Cross-Sectional Study.

International journal of sexual health : official journal of the World Association for Sexual Health·2024
Same author

Pharmacogenetic analysis of inter-ethnic variability in the uptake transporter SLCO1B1 gene in Colombian, Mozambican, and Portuguese populations.

BMC medical genomics·2023
Same author

Endometrial Cancer Staging: Is There Value in ADC?

Journal of personalized medicine·2023
Same author

<i>Allophylus africanus</i> Stem Bark Extract Modulates the Mitochondrial Apoptotic Pathway in Human Stomach Cancer Cells.

Life (Basel, Switzerland)·2023
Same author

Fine scale genetics reveals the subtle negative effects of roads on an endangered bat.

The Science of the total environment·2023

Related Experiment Video

Updated: Jan 23, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

1.9K

CYP2C8 polymorphism among the Portuguese.

Isa Cavaco1, Rita Piedade, J Pedro Gil

  • 1Laboratory of Molecular Toxicology, Centre for Molecular and Structural Biomedicine (CBME), University of Algarve, Faro, Portugal.

Clinical Chemistry and Laboratory Medicine
|February 16, 2006
PubMed
Summary
This summary is machine-generated.

Genetic variations in Cytochrome P450 2C8 (CYP2C8) affect drug metabolism. This study found specific CYP2C8 allele frequencies in Portuguese Caucasians, with CYP2C8*3 being notably higher than in Northern European populations.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.4K
The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform
10:01

The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform

Published on: September 27, 2016

8.0K

Related Experiment Videos

Last Updated: Jan 23, 2026

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing
07:24

Genotyping Single Nucleotide Polymorphisms in the Mitochondrial Genome by Pyrosequencing

Published on: February 10, 2023

1.9K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.4K
The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform
10:01

The Visual Colorimetric Detection of Multi-nucleotide Polymorphisms on a Pneumatic Droplet Manipulation Platform

Published on: September 27, 2016

8.0K

Area of Science:

  • Pharmacogenomics
  • Drug Metabolism
  • Enzyme Kinetics

Background:

  • Cytochrome P450 2C8 (CYP2C8) is a key phase I enzyme responsible for metabolizing numerous xenobiotics.
  • CYP2C8 genetic polymorphisms can influence the efficacy and safety of drugs like paclitaxel and verapamil.
  • Understanding CYP2C8 allele frequencies is crucial for personalized medicine and predicting drug responses.

Purpose of the Study:

  • To determine the allelic frequencies of major non-synonymous CYP2C8 variants (*2, *3, and *4) in a Portuguese Caucasian population.
  • To compare these frequencies with those reported in other ethnic groups, particularly North Europeans.
  • To assess the potential clinical implications of CYP2C8 genetic variability in drug metabolism for this population.

Main Methods:

  • Genotyping of CYP2C8 alleles (CYP2C8*2, CYP2C8*3, CYP2C8*4) using a representative sample of Portuguese Caucasians.
  • Analysis of specific genetic variants: 805A>T (CYP2C8*2), 416G>A/1196A>G (CYP2C8*3), and 792C>G (CYP2C8*4).
  • Statistical comparison of determined allelic frequencies with existing data from other populations.

Main Results:

  • The allelic frequencies for CYP2C8*2, CYP2C8*3, and CYP2C8*4 in Portuguese Caucasians were found to be 1.2%, 19.8%, and 6.4%, respectively.
  • The prevalence of the CYP2C8*3 allele in this Portuguese cohort is significantly higher compared to previously reported frequencies in North European populations.
  • Allele frequencies for CYP2C8*2 and CYP2C8*4 showed distinct patterns within the studied population.

Conclusions:

  • The genetic landscape of CYP2C8 in Portuguese Caucasians differs notably from North European populations, particularly concerning the CYP2C8*3 allele.
  • These findings highlight the importance of population-specific pharmacogenetic data for optimizing drug therapy.
  • Further research is warranted to investigate the functional impact of these observed CYP2C8 allele frequencies on drug metabolism and clinical outcomes in Portugal.